Core Viewpoint - The Law Offices of Howard G. Smith is announcing a class action lawsuit against SLM Corporation (Sallie Mae) for securities fraud, inviting investors who have suffered significant losses to participate in the lawsuit [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that between July 25, 2025, and August 14, 2025, SLM Corporation failed to disclose a significant increase in early-stage delinquencies [3]. - It is claimed that SLM overstated the effectiveness of its loss mitigation and loan modification programs, as well as the overall stability of its PEL delinquency rates [3]. - The lawsuit argues that the positive statements made by SLM regarding its business operations and prospects were materially misleading and lacked a reasonable basis during the relevant time period [3].

Core Viewpoint - Hagens Berman is alerting investors about a pending securities class action lawsuit against Primo Brands Corporation, with a lead plaintiff deadline of January 12, 2026, for those who suffered significant losses [1][5]. Group 1: Allegations and Lawsuit Details - The lawsuit aims to recover losses incurred by investors due to undisclosed operational crises following the merger of Primo Water and BlueTriton Brands, which management claimed was a "flawless" integration [2][4]. - The complaint highlights a contradiction between management's assurances and the new CEO's admission of "self-inflicted" disruptions affecting the ReadyRefresh delivery business [4]. - The first disclosure event occurred on August 7, 2025, when the company reported weak Q2 results and reduced guidance, leading to a 9% stock drop [6]. - The final disclosure event on November 6, 2025, involved a significant reduction in full-year adjusted EBITDA guidance and the replacement of the CEO, resulting in a 21% stock crash [3][6]. Group 2: Operational Issues - The lawsuit emphasizes that the company concealed severe operational risks related to the merger integration, which led to technology breakdowns, supply disruptions, and customer service issues [6]. - The new CEO's comments confirmed the severity of these undisclosed operational issues, which were described as "self-inflicted" [6]. Group 3: Next Steps for Investors - Hagens Berman is advising investors who purchased PRMB shares during the Class Period (June 17, 2024 – November 6, 2025) and experienced substantial losses to contact the firm [5][6]. - Whistleblowers with non-public information regarding Primo are encouraged to consider their options to assist in the investigation [7].

Core Viewpoint - CarMax, Inc. is facing a securities fraud class action lawsuit due to significant revenue and profit declines reported in its second quarter 2026 financial results, which led to a substantial drop in its share price [2][3][4]. Financial Performance - For the second quarter of 2026, CarMax reported a revenue decline of 6.0% year over year, with total retail used vehicle revenues decreasing by 7.2% and total gross profit declining by 5.6% [2]. - The company attributed these declines to inventory adjustments and a $71.3 million increase in loan loss provisions [2]. Share Price Impact - Following the financial results announcement on September 25, 2025, CarMax's share price fell by $11.45, or 20.1%, closing at $45.60 per share [3]. Lawsuit Details - The class action lawsuit alleges that CarMax's management made materially false and misleading statements regarding the company's growth prospects, which were overstated and not reflective of the actual business conditions [4]. - Specifically, it is claimed that the earlier growth in the 2026 fiscal year was a temporary effect driven by customer speculation regarding tariffs, which was not disclosed to investors [4]. Participation Information - Investors who acquired CarMax securities between June 20, 2025, and November 5, 2025, have until January 2, 2026, to seek appointment as lead plaintiff in the class action lawsuit [5].

Core Viewpoint - The article discusses a pending securities class action lawsuit against Stride, Inc. (NYSE: LRN) related to alleged fraudulent practices that led to significant investor losses, with a lead plaintiff deadline set for January 12, 2026 [1][9]. Allegations of Fraud - The lawsuit claims that Stride engaged in two fraudulent schemes: inflating enrollment figures through "Ghost Students" and failing to disclose a critical technology platform failure [2][5]. - The alleged fraudulent activities resulted in a 54% stock crash in a single day, leading to billions in market capitalization losses [2][8]. Specific Allegations - **Enrollment Fraud**: Stride is accused of using "Ghost Students" to artificially inflate enrollment metrics, which misled investors about the company's financial health. This initial disclosure caused an 11% drop in stock price [6]. - **Technology Catastrophe**: The company allegedly concealed severe issues with a platform upgrade that blocked access for 10,000 to 15,000 students, leading to a forecasted sales growth decline from 19% to only 5%, which contributed to the 54% stock crash [7][8]. Legal Proceedings - The complaint seeks to recover losses for investors who purchased LRN securities during the Class Period from October 22, 2024, to October 28, 2025, holding Stride and its executives accountable for misrepresentations [9]. - Hagens Berman, the law firm handling the case, emphasizes the systematic nature of the alleged fraud and is actively gathering evidence to support the claims [4][10].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][5]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, causing a bottleneck in revenue generation [4]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V product, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed the necessary training and onboarding for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the Lead Plaintiff Deadline of January 5, 2026 [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that management prioritized a narrative of seamless transition over actual operational realities [5]. - Whistleblowers with non-public information regarding Inspire are encouraged to assist in the investigation, with potential rewards of up to 30% of any successful recovery made by the SEC [6].

Core Viewpoint - The article highlights the upcoming January 5, 2026 deadline for investors to participate as lead plaintiffs in a securities fraud class action lawsuit against Six Flags Entertainment Corporation related to its merger with Cedar Fair, L.P. [1] Group 1 - The lawsuit is filed on behalf of investors who acquired Six Flags common stock pursuant to the Company's registration statement and prospectus issued in connection with the merger [1]

Core Viewpoint - A class action lawsuit has been filed against Sprouts Farmers Market, Inc. for alleged violations of federal securities laws during the specified Class Period from June 4, 2025, to October 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Sprouts securities during the Class Period [2]. - The Complaint alleges that Defendants made materially false and misleading statements and failed to disclose critical information regarding the company's performance and market conditions [3][8]. Group 2: Allegations Against Defendants - The growth potential for Sprouts in fiscal year 2025 was allegedly overstated [8]. - Defendants assured investors that the customer base would remain resilient against macroeconomic pressures, which was later contradicted by actual sales performance [8]. - It was concealed that a more cautious consumer environment could lead to a significant slowdown in sales growth, undermining the expected benefits from perceived market tailwinds [8]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only collect fees if the case is successful [4]. - The firm has a history of recovering substantial amounts for investors in securities fraud class actions [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the reality of falling demand and revenue [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' estimates [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. - Following this announcement, Integer's stock price dropped by $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to customers having excess inventory of older devices [6]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. and its senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Stride, Inc. is an education technology company that provides an online platform to students across the U.S. [4]. Allegations and Stock Impact - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," ignored compliance requirements, and had a poor customer experience leading to higher withdrawal rates and lower conversion rates [4]. - On September 14, 2025, a report of fraud allegations caused Stride's stock to drop by $18.60 per share, over 11%, from $158.36 to $139.76 [5]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48 per share, more than 54%, from $153.53 to $70.05 [6]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia, under the case caption MacMahon v. Stride, Inc., et al. [3].